We should also mention that a clear trend toward improved survival can be seen with the patients treated with sorafenib at a dose intensity of 50%‐75% (Figure 2 ) and perhaps the lack of statistically significant survival benefit may be a function of the sample size.
← all excerpts
Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database.
1
—
—